Paper28296253
Editorial: Rituximab in the Treatment of Sjögren's Syndrome: Is It the Right or Wrong Drug?
Bootsma H and 2 others. Arthritis Rheumatol, 2017. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. Editorial: Rituximab in the Treatment of Sjögren's Syndrome: Is It the Right or Wrong Drug? Papers, record 28296253. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28296253
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Editorial: Rituximab in the Treatment of Sjögren's Syndrome: Is It the Right or Wrong Drug?
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Sjogren's Syndrome | Major topic |
| Xerostomia | Major topic |
| Cost-Benefit Analysis | |
| Fatigue | |
| Humans | |
| Rituximab |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment on | 28296257 | Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. | https://conductscience.org/library/papers/28296257 |
Source PubMed
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41811912 | Immunophenotypic Stratification of Primary Sjögren's Syndrome Reveals Distinct Lymphocyte Profiles and Clinical Manifestations. | J Immunol Res | 2026 | https://conductscience.org/library/papers/41811912 | PubMed |
| 38148483 | The minimally important difference for the Xerostomia Inventory among Sjögren's disease patients. | Oral Dis | 2024 | https://conductscience.org/library/papers/38148483 | PubMed |
| 37373845 | Intraoperative Visualization and Treatment of Salivary Gland Dysfunction in Sjögren's Syndrome Patients Using Contrast-Enhanced Ultrasound Sialendoscopy (CEUSS). | J Clin Med | 2023 | https://conductscience.org/library/papers/37373845 | PubMed |
| 32949144 | Sialendoscopy increases saliva secretion and reduces xerostomia up to 60 weeks in Sjögren's syndrome patients: a randomized controlled study. | Rheumatology (Oxford) | 2021 | https://conductscience.org/library/papers/32949144 | PubMed |
| 30647480 | Subgroups of Sjögren's syndrome patients categorised by serological profiles: clinical and immunological characteristics. | Reumatologia | 2018 | https://conductscience.org/library/papers/30647480 | PubMed |
| 29416129 | B cells in the pathogenesis of primary Sjögren syndrome. | Nat Rev Rheumatol | 2018 | https://conductscience.org/library/papers/29416129 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28296253
GET https://conductscience.org/api/papers/v1/28296253/authors